John Lennon said that life is what happens when you’re busy making other plans. For DexCom Inc., that’s not a bad thing. Founded in 1999, DexCom tried, but failed, to develop a fully implantable glucose sensor that would last for at least a year and help patients with diabetes avoid the numerous daily finger-sticks required to measure their blood glucose. Along the way, however, it did succeed in gaining FDA approval for a sensor that enables continuous glucose monitoring (CGM) for seven days at a time, and that may be enough to revolutionize diabetes care.
CGM is a hot topic at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?